$IMRN News

Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference

Travelan® Phase 2 Study Results Published

Immuron Announces Publication Of Data From Its Phase 2 Clinical Trial Of Once-Daily Oral Travelan In 'Scientific Reports'; Statistically Significant 50% Reduction In ETEC Challenge-Related Adverse Events Versus Placebo

Immuron Limited (IMRN) Presents at Coffee Microcaps Conference 2026 - Slideshow

IMRN Stock Skyrockets 60%, Heads For Best Day In Over 2 Years – What’s Driving The Super Rally Today?

Immuron Plans U.S. PROIBS Launch Under Exclusive Distribution Agreement

Immuron to launch PROIBS® in the United States

Immuron Stock Surges Friday: What's Driving the Action?

Immuron Reports FY26 Preliminary Results

Immuron Limited (IMRN) Presents at 95th Emerging Growth Conference - Slideshow

Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar

Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year

Immuron Sees Prelim FY2026 Sales $5.462M

Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy

Immuron Hires Pullan To Find Partner For Gut Infection Drug, Seeks Strategic Partner For FDA-Cleared IMM-529 Trial

Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00

Immuron shares are trading higher after the company reported a year-over-year increase in its Q3 sales results.

Immuron shares are trading higher after the company reported a year-over-year increase in its Q3 sales results.

Immuron Double Digit 3Q Sales Growth

Immuron Reports Q3 Sales A$1.5M, Up 16% YoY